Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

Pharmacogenetics

Volumn 12, Issue 2, 2002, Pages 101-109

  Kirchheiner, Julia ^a   Bauer, Steffen ^a   Meineke, Ingolf ^a   Rohde, Wolfgang ^a   Prang, Verena ^a   Meisel, Christian ^a   Roots, Ivor ^a   Brockmöller, Jürgen ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

CYP2C19; CYP2C9; Diabetes; Pharmacogenetics; Population pharmacokinetics; Tolbutamide

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; GLUCOSE; INSULIN; TOLBUTAMIDE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CODOMINANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BLOOD GLUCOSE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION; FEMALE; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; POPULATION SURVEILLANCE; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TIME FACTORS; TOLBUTAMIDE;

EID: 0036220552     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200203000-00004     Document Type: Article

References (34)

1. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
2. Cytochrome P4502C9: An enzyme of major importance in human drug meabolism
3. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations
4. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
5. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily
6. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9
7. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes
8. The metabolic fate of tolbutamide in man and in the rat
9. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9
10. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers
11. Pharmacogenetics of tolbutamide metabolism in humans
12. Clinical pharmacology of sulphonylurea hypoglycaemic agents: Part 1
13. A screening test for slow metabolisers of tolbutamide
14. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype
15. Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser
16. Tolbutamide hydroxylation in humans: Lack of bimodality in 106 healthy subjects
17. Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition
18. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes
19. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
20. A novel extravascular input function for the assessment of drug absorption in bioavailability studies
21. Assessment of insulin sensitivity and secretion with the labelled intravenous glucose tolerance test: Improved modelling analysis
22. Population-based modeling to demonstrate extrapancreatic effects of tolbutamide
23. Allelic and functional variability of cytochrome P4502C9
24. Genetic analysis of the human cytochrome P450 CYP2C9 locus
25. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family
26. Phenytoin: Pharmacogenetic polymorphism of 4′-hydroxylation
27. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174
28. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9* 3 allele
29. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
30. The regulation of glucose-induced insulin secretion by pre-stimulus glucose level and tolbutamide in normal man
31. Single daily doses of tolbutamide (Rastinon) in the treatment of diabetes mellitus
32. Dose-response relationships of tolbutamide and glibenclamide in diabetes mellitus
33. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment